Operating Metrics 營運指標
Boston Scientific Corporation (BSX) Operating Metrics 營運指標
Boston Scientific Corporation BSX 最近 8 季公司營運 KPI、指標定義、跨期趨勢與官方來源。
資料截至：2026-06-30
最新營運指標
- Endoscopy Sales
- $3,036M · 2026-06-30 來源：Boston Scientific Corporation、Boston Scientific Corporation、Boston Scientific Corporation、Boston Scientific Corporation
- Urology Sales
- $2,729M · 2026-06-30 來源：Boston Scientific Corporation、Boston Scientific Corporation、Boston Scientific Corporation、Boston Scientific Corporation
- Neuromodulation Sales
- $1,284M · 2026-06-30 來源：Boston Scientific Corporation、Boston Scientific Corporation、Boston Scientific Corporation、Boston Scientific Corporation
- Interventional Cardiology & Vascular Therapies Sales
- $4,914M · 2026-06-30 來源：Boston Scientific Corporation、Boston Scientific Corporation、Boston Scientific Corporation
- WATCHMAN Sales
- $2,060M · 2026-06-30 來源：Boston Scientific Corporation、Boston Scientific Corporation、Boston Scientific Corporation
- Electrophysiology Sales
- $3,576M · 2026-06-30 來源：Boston Scientific Corporation、Boston Scientific Corporation、Boston Scientific Corporation
- Cardiac Rhythm Management Sales
- $2,328M · 2026-06-30 來源：Boston Scientific Corporation、Boston Scientific Corporation、Boston Scientific Corporation
- Interventional Oncology & Embolization Sales
- $1,067M · 2026-06-30 來源：Boston Scientific Corporation、Boston Scientific Corporation、Boston Scientific Corporation
季度趨勢
| 指標 | Q2 FY2026 | Q1 FY2026 | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 | Q4 FY2024 | Q3 FY2024 |
|---|---|---|---|---|---|---|---|---|
| Endoscopy Sales | $793M | $736M | $760M | $747M | $737M | $673M | $690M | $678M |
| Urology Sales | $684M | $646M | $717M | $682M | $676M | $633M | $630M | $532M |
| Neuromodulation Sales | $341M | $318M | $332M | $293M | $303M | $271M | $299M | $268M |
| Interventional Cardiology & Vascular Therapies Sales | $1,333M | $1,244M | $1,202M | $1,135M | $1,178M | $1,124M | $1,091M | $1,047M |
| WATCHMAN Sales | $507M | $506M | $535M | $512M | $486M | $425M | $413M | $380M |
| Electrophysiology Sales | $916M | $905M | $890M | $865M | $840M | $730M | $649M | $527M |
| Cardiac Rhythm Management Sales | $585M | $578M | $587M | $578M | $590M | $578M | $566M | $561M |
| Interventional Oncology & Embolization Sales | $283M | $268M | $263M | $253M | $251M | $228M | $222M | $215M |
| Days Sales Outstanding | 51 days | 52 days | 51 days | 51 days | 51 days | 52 days | 52 days | 55 days |
| Days Inventory on Hand | 185 days | 177 days | 168 days | 177 days | 159 days | 178 days | 176 days | 193 days |
資料來源
- Q2 2026 Financial & Operational Highlights · Boston Scientific Corporation · 2026-07-29
- Q1 2026 Financial & Operational Highlights · Boston Scientific Corporation · 2026-04-22
- Q4 2025 Financial & Operational Highlights — Cardiovascular Breakout · Boston Scientific Corporation · 2026-02-04
- Q3 2025 Financial & Operational Highlights · Boston Scientific Corporation · 2025-10-22